Safety and efficacy of CPX-351 in younger patients (<60 years old) with secondary acute myeloid leukemia-Reference-Cited by-同舟云学术

Safety and efficacy of CPX-351 in younger patients (<60 years old) with secondary acute myeloid leukemia

Published:2023-03-23 Issue:12 Volume:141 Page:1489-1493
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Przespolewski Amanda¹^ORCID,Goldberg Aaron D.²^ORCID,Talati Chetasi³⁴,Fazal Salman⁵,Vachhani Pankit⁶^ORCID,Sanikommu Srinivasa R.⁷,Thota Swapna¹⁸^ORCID,Waksal Julian²⁹^ORCID,Ball Brian²¹⁰,Famulare Christopher²,Stahl Maximilian²¹¹,Baron Jeffrey¹²^ORCID,Griffiths Elizabeth A.¹^ORCID,Thompson James E.¹^ORCID,Sweet Kendra³,Wang Eunice S.¹

Affiliation:

1. 1Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY

2. 2Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY

3. 3Moffitt Cancer Center, Tampa, FL

4. 4AbbVie Inc, North Chicago, IL

5. 5Allegheny Health Network, Pittsburgh, PA

6. 6O'Neal Comprehensive Cancer Center at The University of Alabama at Birmingham, Birmingham, AL

7. 7Levine Cancer Institute, Charlotte, NC

8. 8The University of Tennessee Health Science Center, Memphis, TN

9. 9Department of Hematology and Oncology, Icahn School of Medicine at Mount Sinai, New York, NY

10. 10Department of Hematology and Hematopoietic Stem Cell Transplantation, City of Hope Cancer Center, Duarte, CA

11. 11Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA

12. 12Department of Pharmacy, Roswell Park Comprehensive Cancer Center, Buffalo, NY

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

https://ashpublications.org/blood/article-pdf/141/12/1489/2040037/blood_bld-2022-016678-main.pdf

Reference11 articles.

1. Characterization and prognostic features of secondary acute myeloid leukemia in a population-based setting: a report from the Swedish Acute Leukemia Registry;Hulegardh;Am J Hematol,2015

2. Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: a PETHEMA registry study;Martinez-Cuadron;Blood Adv,2022

3. CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia;Lancet;J Clin Oncol,2018

4. CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial;Lancet;Lancet Haematol,2021

5. Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia;Cheson;J Clin Oncol,2003